Frontier Science Partners With SUNY Stony Brook On cCMV Study

Frontier Science is proud to announce its partnership with SUNY Stony Brook and New York State on the Prospective Observational Study of Asymptomatic cCMV Transmission to Infants for Virological Evaluation in New York State (PROACTIVE NYS). Frontier Science serves as the Statistical and Data Management Center, providing a wide range of technical services and support for the data management and statistical needs of the project.


Cytomegalovirus (CMV) is the most common congenital infection worldwide, estimated to occur in 0.6% of all pregnancies. Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, this systematic, longitudinal cohort study aims to:

  • Determine the rate of confirmed congenital CMV (cCMV) in a statewide cohort
  • Describe the distribution of neonatal features among children with confirmed cCMV
  • Describe trends in antiviral and non-pharmaceutical treatments, adverse effects, and impact on long-term outcomes
  • Assess the long-term (2 year) audiologic, neurologic, and developmental outcomes of children with cCMV
  • Describe the impact of a positive cCMV screen on the quality of life of infants and families.

Both the Frontier Science and SUNY Stony Brook teams are excited about this groundbreaking project. With study activities currently underway, Frontier Science is pioneering the use of Research Electronic Data Capture (REDCap) as the electronic data capture system for PROACTIVE NYS.

The study kick-off meeting, held in November, was a productive discussion between the study Principal Investigators, New York State Department of Health, Frontier Science, and other important collaborators. With enrollment starting in early December, PROACTIVE NYS is poised to be another success for the Frontier Science portfolio

To learn more about this study, please visit the PROACTIVE NYS web site.